TABLE OF CONTENTS

1 INTRODUCTION 19
1.1 OBJECTIVES OF THE STUDY 19
1.2 MARKET DEFINITION 19
1.3 SCOPE OF THE STUDY 20
1.3.1 MARKETS COVERED 20
1.3.2 YEARS CONSIDERED FOR THE STUDY 21
1.4 CURRENCY 21
1.5 STAKEHOLDERS 21
2 RESEARCH METHODOLOGY 22
2.1 RESEARCH APPROACH 22
2.1.1 SECONDARY SOURCES 23
2.1.1.1 Key data from secondary sources 23
2.1.2 PRIMARY SOURCES 24
2.1.2.1 Key data from primary sources 24
2.1.2.2 Key industry insights 25
2.2 MARKET SIZE ESTIMATION 26
2.2.1 BOTTOM-UP APPROACH 26
2.2.2 TOP-DOWN APPROACH 27
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 28
2.4 MARKET SHARE ESTIMATION 29
2.5 ASSUMPTIONS FOR THE STUDY 29
2.6 LIMITATIONS 29
3 EXECUTIVE SUMMARY 30
4 PREMIUM INSIGHTS 34
4.1 PLASMA FRACTIONATION MARKET OVERVIEW 34
4.2 ASIA PACIFIC: PLASMA FRACTIONATION MARKET, BY PRODUCT, 2018 35
4.3 GEOGRAPHICAL SNAPSHOT OF THE PLASMA FRACTIONATION MARKET 36
4.4 PLASMA FRACTIONATION MARKET: REGIONAL MIX 37
4.5 PLASMA FRACTIONATION MARKET, DEVELOPING COUNTRIES VS.
DEVELOPED COUNTRIES 37
 
5 MARKET OVERVIEW 38
5.1 INTRODUCTION 38
5.2 MARKET DYNAMICS 38
5.2.1 MARKET DRIVERS 39
5.2.1.1 Growing use of immunoglobulins in various therapeutic areas 39
5.2.1.2 Rising geriatric population across the globe 40
5.2.1.3 Growing prevalence of respiratory diseases and AATD driving the uptake of alpha-1-antitrypsin 41
5.2.1.4 Increase in plasma collection 42
5.2.2 MARKET RESTRAINTS 44
5.2.2.1 High cost and limited reimbursement 44
5.2.2.2 Emergence of recombinant alternatives 44
5.2.3 MARKET OPPORTUNITY 45
5.2.3.1 Increasing number of hemophilia patients 45
5.2.4 MARKET CHALLENGE 46
5.2.4.1 Stringent government regulations 46
6 INDUSTRY INSIGHTS 48
6.1 INTRODUCTION 48
6.2 KEY INDUSTRY TRENDS 49
6.2.1 FOCUS ON INCREASING FRACTIONATION CAPACITIES AND GEOGRAPHICAL EXPANSIONS 50
6.2.2 NEW INDICATIONS FOR PLASMA PRODUCTS 51
6.2.3 RISING ADOPTION OF SCIG 51
6.2.4 INCREASING NUMBER OF FRACTIONATOR-OWNED PLASMA COLLECTION CENTERS 52
6.2.5 GROWING PLASMA PRODUCTS MARKET IN CHINA 53
6.2.6 INCREASING FOCUS OF PLASMA FRACTIONATORS TOWARDS MANUFACTURING AND DEVELOPING RECOMBINANT FACTORS 55
6.3 PORTER’S FIVE FORCES 57
6.3.1 THREAT FROM NEW ENTRANTS 57
6.3.2 THREAT OF SUBSTITUTES 58
6.3.3 BARGAINING POWER OF SUPPLIERS 58
6.3.4 BARGAINING POWER OF BUYERS 59
6.3.5 INTENSITY OF COMPETITIVE RIVALRY 59
6.4 VENDOR BENCHMARKING 60
 
7 PLASMA FRACTIONATION MARKET, BY PRODUCT 62
7.1 INTRODUCTION 63
7.2 IMMUNOGLOBULIN 64
7.2.1 INTRAVENOUS IMMUNOGLOBULIN (IVIG) 66
7.2.2 SUBCUTANEOUS IMMUNOGLOBULIN (SCIG) 70
7.2.3 OTHER IMMUNOGLOBULINS 72
7.3 COAGULATION FACTOR CONCENTRATES 75
7.3.1 FACTOR VIII 77
7.3.2 FACTOR IX 80
7.3.3 VON WILLEBRAND FACTOR 83
7.3.4 PROTHROMBIN COMPLEX CONCENTRATE 84
7.3.5 FIBRINOGEN CONCENTRATES 86
7.3.6 FACTOR XIII 87
7.4 ALBUMIN 89
7.5 PROTEASE INHIBITORS 92
7.6 OTHER PLASMA PRODUCTS 94
8 PLASMA FRACTIONATION MARKET, BY APPLICATION 95
8.1 INTRODUCTION 96
8.2 NEUROLOGY 97
8.3 IMMUNOLOGY 99
8.4 HEMATOLOGY 101
8.5 CRITICAL CARE 104
8.6 PULMONOLOGY 105
8.7 HEMATO-ONCOLOGY 107
8.8 RHEUMATOLOGY 108
8.9 OTHER APPLICATIONS 110
9 PLASMA FRACTIONATION MARKET, BY END USER 112
9.1 INTRODUCTION 113
9.2 HOSPITALS & CLINICS 114
9.3 CLINICAL RESEARCH LABORATORIES 115
9.4 ACADEMIC INSTITUTES 117
10 GEOGRAPHIC ANALYSIS 119
10.1 INTRODUCTION 120
10.2 NORTH AMERICA 122
10.2.1 US 127
10.2.2 CANADA 132
 
10.3 EUROPE 135
10.3.1 GERMANY 141
10.3.2 FRANCE 145
10.3.3 ITALY 148
10.3.4 SPAIN 152
10.3.5 UK 155
10.3.6 REST OF EUROPE 159
10.4 ASIA PACIFIC 163
10.4.1 CHINA 167
10.4.2 JAPAN 170
10.4.3 INDIA 174
10.4.4 MALAYSIA 177
10.4.5 REST OF ASIA PACIFIC 181
10.5 LATIN AMERICA 184
10.6 MIDDLE EAST & AFRICA 187
11 COMPETITIVE LANDSCAPE 191
11.1 OVERVIEW 191
11.2 MARKET SHARE ANALYSIS 192
11.3 COMPETITIVE SCENARIO AND TRENDS 194
11.3.1 EXPANSIONS 194
11.3.2 PRODUCT LAUNCHES 195
11.3.3 ACQUISITIONS 195
11.3.4 AGREEMENTS, COLLABORATIONS, JOINT VENTURES, AND PARTNERSHIPS 196
12 COMPANY PROFILES 197
(Overview, Strength of Product Portfolio, Business Strategy Excellence, Products Offering, and Recent Developments)*
12.1 CSL 197
12.2 GRIFOLS 201
12.3 SHIRE 205
12.4 OCTAPHARMA 209
12.5 KEDRION 211
12.6 LFB 215
12.7 BIOTEST 218
12.8 SANQUIN 221
12.9 CHINA BIOLOGIC PRODUCTS 223
12.10 BIO PRODUCTS LABORATORY (BPL) 226
 
12.11 JAPAN BLOOD PRODUCTS ORGANIZATION 228
12.12 GREEN CROSS CORPORATION 231
12.13 SHANGHAI RAAS BLOOD PRODUCTS 234
*Details on Overview, Strength of Product Portfolio, Business Strategy Excellence, Products Offering, and Recent Developments might not be captured in case of unlisted companies.
13 APPENDIX 236
13.1 INSIGHTS OF INDUSTRY EXPERTS 236
13.2 DISCUSSION GUIDE 237
13.3 AVAILABLE CUSTOMIZATION 241
13.4 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 242
13.5 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 244
13.6 RELATED REPORT 246
13.7 AUTHOR DETAILS 247